Literature DB >> 24531700

Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients.

Charles M Balch1, John F Thompson, Jeffrey E Gershenwald, Seng-Jaw Soong, Shouluan Ding, Kelly M McMasters, Daniel G Coit, Alexander M M Eggermont, Phyllis A Gimotty, Timothy M Johnson, John M Kirkwood, Stanley P Leong, Merrick I Ross, David R Byrd, Alistair J Cochran, Martin C Mihm, Donald L Morton, Michael B Atkins, Keith T Flaherty, Vernon K Sondak.   

Abstract

PURPOSE: We have previously reported that older patients with clinical stage I and II primary cutaneous. Melanoma had lower survival rates compared to younger patients. We postulated that the incidence of nodal metastasis would therefore be higher among older melanoma patients.
METHODS: The expanded American Joint Committee on Cancer melanoma staging database contains a cohort of 7,756 melanoma patients who presented without clinical evidence of regional lymph node or distant metastasis and who underwent a sentinel node biopsy procedure as a component of their staging assessment.
RESULTS: Although older patients had primary melanoma features associated with more aggressive biology, we paradoxically observed a significant decrease in the incidence of sentinel node metastasis as patient age increased. Overall, the highest incidence of sentinel node metastasis was 25.8 % in patients under 20 years of age, compared to 15.5 % in patients 80 years and older (p < 0.001). In contrast, 5-year mortality rates for clinical stage II patients ranged from a low of 20 % for those 20-40 years of age up to 38 % for those over 70 years of age. Patient age was an independent predictor of sentinel node metastasis in a multifactorial analysis (p < 0.001).
CONCLUSIONS: Patients with clinical stage I and II melanoma under 20 years of age had a higher incidence of sentinel lymph node metastasis but, paradoxically, a more favorable survival outcome compared to all other age groups. In contrast, patients >70 years had the most aggressive primary melanoma features and a higher mortality rate compared to all other age groups but a lower incidence of sentinel lymph node metastasis.

Entities:  

Mesh:

Year:  2014        PMID: 24531700      PMCID: PMC4121329          DOI: 10.1245/s10434-013-3464-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  47 in total

1.  Senile changes in human lymph nodes.

Authors:  Wei-Ren Pan; Hiroo Suami; G Ian Taylor
Journal:  Lymphat Res Biol       Date:  2008       Impact factor: 2.589

2.  Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database.

Authors:  Richard L White; Gregory D Ayers; Virginia H Stell; Shouluan Ding; Jeffrey E Gershenwald; Jonathan C Salo; Barbara A Pockaj; Richard Essner; Mark Faries; Kim James Charney; Eli Avisar; Axel Hauschild; Friederike Egberts; Bruce J Averbook; Carlos A Garberoglio; John T Vetto; Merrick I Ross; David Chu; Vijay Trisal; Harald Hoekstra; Eric Whitman; Harold J Wanebo; Daniel Debonis; Michael Vezeridis; Aaron Chevinsky; Mohammed Kashani-Sabet; Yu Shyr; Lynne Berry; Zhiguo Zhao; Seng-Jaw Soong; Stanley P L Leong
Journal:  Ann Surg Oncol       Date:  2011-06-07       Impact factor: 5.344

3.  Prognostic factors for melanoma in children and adolescents: a clinicopathologic, single-center study of 137 Patients.

Authors:  Sabela Paradela; Eduardo Fonseca; Salvador Pita-Fernández; Sara M Kantrow; Abdul H Diwan; Cynthia Herzog; Victor G Prieto
Journal:  Cancer       Date:  2010-09-15       Impact factor: 6.860

4.  Age as a prognostic factor in patients with localized melanoma and regional metastases.

Authors:  Charles M Balch; Seng-jaw Soong; Jeffrey E Gershenwald; John F Thompson; Daniel G Coit; Michael B Atkins; Shouluan Ding; Alistair J Cochran; Alexander M M Eggermont; Keith T Flaherty; Phyllis A Gimotty; Timothy M Johnson; John M Kirkwood; Stanley P Leong; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Vernon K Sondak
Journal:  Ann Surg Oncol       Date:  2013-07-10       Impact factor: 5.344

5.  Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma.

Authors:  Farhad Azimi; Richard A Scolyer; Pavlina Rumcheva; Marc Moncrieff; Rajmohan Murali; Stanley W McCarthy; Robyn P Saw; John F Thompson
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

6.  Sentinel node biopsy in atypical melanocytic neoplasms in childhood: a single institution experience in 24 patients.

Authors:  Omie L Mills; Suroosh Marzban; Jonathan S Zager; Vernon K Sondak; Jane L Messina
Journal:  J Cutan Pathol       Date:  2012-03       Impact factor: 1.587

7.  Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database.

Authors:  John J Strouse; Thomas R Fears; Margaret A Tucker; Alan S Wayne
Journal:  J Clin Oncol       Date:  2005-07-20       Impact factor: 44.544

8.  Age-related lymphatic dysfunction in melanoma patients.

Authors:  W Charles Conway; Mark B Faries; Michael B Nicholl; Alicia M Terando; Edwin C Glass; MyungShin Sim; Donald L Morton
Journal:  Ann Surg Oncol       Date:  2009-03-11       Impact factor: 5.344

9.  Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients.

Authors:  Dennis L Rousseau; Merrick I Ross; Marcella M Johnson; Victor G Prieto; Jeffrey E Lee; Paul F Mansfield; Jeffrey E Gershenwald
Journal:  Ann Surg Oncol       Date:  2003-06       Impact factor: 5.344

10.  The complex relationships between sentinel node positivity, patient age, and primary tumor desmoplasia: analysis of 2303 melanoma patients treated at a single center.

Authors:  Sander Sassen; Helen M Shaw; Marjorie H Colman; Richard A Scolyer; John F Thompson
Journal:  Ann Surg Oncol       Date:  2007-12-14       Impact factor: 5.344

View more
  28 in total

1.  Trends in the diagnosis and clinical features of melanoma in situ (MIS) in US men and women: A prospective, observational study.

Authors:  Erin X Wei; Abrar A Qureshi; Jiali Han; Tricia Y Li; Eunyoung Cho; Jennifer Y Lin; Wen-Qing Li
Journal:  J Am Acad Dermatol       Date:  2016-07-16       Impact factor: 11.527

2.  Sentinel Lymph Node Biopsy Is Prognostic in Thickest Melanoma Cases and Should Be Performed for Thick Melanomas.

Authors:  Dale Han; Gang Han; Monica T Duque; Steven Morrison; Stanley P Leong; Mohammed Kashani-Sabet; John Vetto; Richard White; Schlomo Schneebaum; Barbara Pockaj; Nicola Mozzillo; Vernon K Sondak; Jonathan S Zager
Journal:  Ann Surg Oncol       Date:  2020-06-10       Impact factor: 5.344

3.  EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma.

Authors:  Christina Bluemel; Ken Herrmann; Francesco Giammarile; Omgo E Nieweg; Julien Dubreuil; Alessandro Testori; Riccardo A Audisio; Odysseas Zoras; Michael Lassmann; Annette H Chakera; Roger Uren; Sotirios Chondrogiannis; Patrick M Colletti; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07-25       Impact factor: 9.236

Review 4.  Lymph nodes and the melanoma surgeon: re-defining a long-term relationship.

Authors:  Mary S Brady
Journal:  Melanoma Manag       Date:  2016-02-24

5.  Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

Authors:  Paolo A Ascierto; Antonio M Grimaldi; Ana Carrizosa Anderson; Carlo Bifulco; Alistair Cochran; Claus Garbe; Alexander M Eggermont; Mark Faries; Soldano Ferrone; Jeffrey E Gershenwald; Thomas F Gajewski; Ruth Halaban; F Stephen Hodi; Richard Kefford; John M Kirkwood; James Larkin; Sancy Leachman; Michele Maio; Richard Marais; Giuseppe Masucci; Ignacio Melero; Giuseppe Palmieri; Igor Puzanov; Antoni Ribas; Yvonne Saenger; Bastian Schilling; Barbara Seliger; David Stroncek; Ryan Sullivan; Alessandro Testori; Ena Wang; Gennaro Ciliberto; Nicola Mozzillo; Francesco M Marincola; Magdalena Thurin
Journal:  J Transl Med       Date:  2014-10-28       Impact factor: 5.531

6.  Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival.

Authors:  Faruk Tas; Kayhan Erturk
Journal:  Mol Clin Oncol       Date:  2017-10-04

7.  Stratifying SLN incidence in intermediate thickness melanoma patients.

Authors:  James M Chang; Heidi E Kosiorek; Amylou C Dueck; Stanley P L Leong; John T Vetto; Richard L White; Eli Avisar; Vernon K Sondak; Jane L Messina; Jonathan S Zager; Carlos Garberoglio; Mohammed Kashani-Sabet; Barbara A Pockaj
Journal:  Am J Surg       Date:  2017-12-14       Impact factor: 2.565

8.  Use and Costs of Sentinel Lymph Node Biopsy in Non-Ulcerated T1b Melanoma: Analysis of a Population-Based Registry.

Authors:  Joshua N Herb; David W Ollila; Karyn B Stitzenberg; Michael O Meyers
Journal:  Ann Surg Oncol       Date:  2021-04-26       Impact factor: 5.344

9.  Association Between Patient Age and Lymph Node Positivity in Thin Melanoma.

Authors:  Andrew J Sinnamon; Madalyn G Neuwirth; Pratyusha Yalamanchi; Phyllis Gimotty; David E Elder; Xiaowei Xu; Rachel R Kelz; Robert E Roses; Emily Y Chu; Michael E Ming; Douglas L Fraker; Giorgos C Karakousis
Journal:  JAMA Dermatol       Date:  2017-09-01       Impact factor: 10.282

10.  Identification of Patients with Intermediate Thickness Melanoma at Low Risk for Sentinel Lymph Node Positivity.

Authors:  Edmund K Bartlett; Madalyn G Peters; Anne Blair; Mark S Etherington; David E Elder; Xiaowei G Xu; DuPont Guerry; Michael E Ming; Douglas L Fraker; Brian J Czerniecki; Phyllis A Gimotty; Giorgos C Karakousis
Journal:  Ann Surg Oncol       Date:  2015-07-28       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.